← Back to Search

Atypical Antipsychotic

Iloperidone for Bipolar Disorder

Phase 3
Waitlist Available
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights

Summary

This trial will compare the effectiveness of iloperidone versus placebo in treating people with acute manic or mixed episodes associated with Bipolar I Disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score

Side effects data

From 2014 Phase 4 trial • 20 Patients • NCT01464229
46%
Dry Mouth
15%
Nausea
15%
Somnolence
15%
Headaches
8%
Cramping
8%
Palpitations
8%
Increased Irritability
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Iloperidone

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: IloperidoneExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloperidone
FDA approved

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
61 Previous Clinical Trials
18,987 Total Patients Enrolled
1 Trials studying Bipolar Disorder
41 Patients Enrolled for Bipolar Disorder
~96 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top